A toolkit to facilitate the analysis and publication of clinical trial costs

While the new draft contains several improvements, governments must address outstanding issues to safeguard equitable access to medical products

The US PASTEUR Act falls short in addressing antimicrobial resistance

Q&A on access to HIV prevention drug CAB-LA

The access barriers on lifesaving TB tools

MSF’s analysis of the proposed negotiating text of the WHO pandemic accord

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Q&A on “Time for $5”, a campaign for affordable diagnostic tests

Principles and actions for equitable access to medical products

The second in a series of roundtables focused on clinical trial cost transparency

Global access to point-of-care CD4 devices and tests is under threat

MSF’s recommendations on the WHO Pandemic Prevention, Preparedness and Response Accord zero draft

Access to long-acting medicines will be key to meeting global HIV prevention and treatment targets.

This policy is a commitment to publishing research protocols, registering clinical trials on appropriate registries, and subsequently publishing clinical trial data in open access formats, in line with the WHO’s joint statement on ...

The UK has tabled harmful provisions that threaten to tighten the screws on producing, supplying and exporting affordable generic medicines from India

Clinical trial cost transparency can inform evidence-based policy making and enable governments and treatment providers to regulate and negotiate prices more effectively.